REACT-AF Trial: Rhythm Evaluation for AntiCoagulaTion with Continuous Monitoring of Atrial Fibrillation

REACT-AF is a multicenter prospective, randomized, open-label, blinded endpoint (PROBE design), controlled trial comparing the current standard of care of continuous DOAC use versus time-delimited (1 month) DOAC guided by an AF-sensing smart watch in participants with a history of non-permanent AF and low-to-moderate stroke risk (CHA₂DS₂-VASc score 1-4 for men, 2-4 for women). Follow-up time will be 3-5 years. The study will be conducted in up to 100 US centers targeting two-thirds academic and one-third private practices, with academic practices also enrolling from affiliated community sites.

ClinicalTrials.gov Identifier: NCT05836987

See the participating clinical sites on the map below. For site details, visit ClinicalTrials.gov